Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.

A human malignant melanoma cell strain, UCLA-SO-M14 (M14), was adapted to grow in serum-free, chemically defined medium (CDM). The 3 M KCl extract prepared from the CDM-grown cells (M-14-CDM) was assayed against leukocytes from melanoma patients, patients with other cancers, and normal donors by leukocyte migration inhibition (LMI). The leukocytes from 15 to 27 (56%) melanoma patients tested were LMI positive. In contrast, 4 of 18 (22%) other cancer patients and 5 of 30 (17%) normal donors leukocytes were LMI positive. One of 14 melanoma patients' leukocytes were LMI positive for a control 3 M KCI extract from autologous muscle. Comparative studies were performed with the M14-CDM extract and a 3 M KCI extract from a freshly biopsied tumor specimen from the donor of the M14 cell strain. Seven of 12 (58%) melanoma patients' leukocytes were LMI positive to the M14-CDM extract, but only 2 of 12 (17%) were LMI positive to the autologous melanoma tissue extract. Furthermore, only 100 to 300 mug protein of M14-CDM extract were required to educe delayed cutaneous hypersensitivity response in 6 of 8 (75%) melanoma patients and 0 of 5 lung cancer patients, but 500 mug protein from biopsied autologous melanoma tissue extract were needed to produce delayed cutaneous hypersensitivity response in 24 of 42 (57%) melanoma patients and 7 of 28 (25%) nonmelanoma cancer patients. These data suggest: (a) the M14-CDM cells synthesized melanoma-associated antigen(s) (MAA) in CDM; (B) the 3 M KCI extraction procedure effectively removed the MAA from the M14-CDM cells; (c) the M14-CDM cells were a more potent source of MAA than the surgical autologous melanoma specimen; and (d) the M14-CDM cells provided a continuous source of standard MAA.

[1]  J. Roth,et al.  Inhibition of human leukocyte migration in agarose by KCl extracts of carcinoma of the lung , 1975, International journal of cancer.

[2]  D. Morton,et al.  Delayed cutaneous hypersensitivity reactions to melanoma antigen. , 1975, Surgery.

[3]  J. Adams,et al.  Tumor-specific immunity in 3-methylcholanthrene-induced murine fibrosarcomas. I. In vivo demonstration of immunity with three preparations of soluble antigens. , 1974, Journal of the National Cancer Institute.

[4]  K. Irie,et al.  Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum. , 1974, Journal of the National Cancer Institute.

[5]  A. Cochran,et al.  Cellular immunity to breast carcinoma and malignant melanoma. , 1973, The British journal of cancer. Supplement.

[6]  J. Blake,et al.  The significance of humoral antibodies in the localization of human malignant melanoma , 1973, The British journal of surgery.

[7]  A. Ketcham,et al.  Demonstration of tumor-associated delayed cutaneous hypersensitivity reactions in patients with lung cancer and in pateients with carcinoma of the cervix. , 1973, National Cancer Institute monograph.

[8]  A. Cochran,et al.  Postoperative Depression of Tumour-directed Cell-mediated Immunity in Patients with Malignant Disease , 1972, British medical journal.

[9]  R. Herberman,et al.  Expression of fetal antigens in tumor cells. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Alexander.  Foetal “Antigens” in Cancer , 1972, Nature.

[11]  M. Meltzer,et al.  Tumor-specific antigen solubilized by hypertonic potassium chloride. , 1971, Journal of the National Cancer Institute.

[12]  W. Wolberg.  Inhibition of migration of human autogenous and allogeneic leukocytes by extracts of patients' cancers. , 1971, Cancer research.

[13]  D. Morton,et al.  Immunological aspects of neoplasia: a rational basis for immunotherapy. , 1971, Annals of internal medicine.

[14]  K. Hellström,et al.  The role of immunological enhancement for the growth of autochthonous tumors. , 1971, Transplantation proceedings.

[15]  J. E. Clausen.  TUBERCULIN‐INDUCED MIGRATION INHIBITION OF HUMAN PERIPHERAL LEUCOCYTES IN AGAROSE MEDIUM , 1971, Acta allergologica.

[16]  H. Sjögren,et al.  Demonstration of cell‐mediated immunity to human neoplasms of various histological types , 1971, International journal of cancer.

[17]  R. Herberman,et al.  Skin-reactive soluble antigen from intestinal cancer-cell-membranes and relationship to carcinoembryonic antigens. , 1970, Lancet.

[18]  J. Ziegler,et al.  Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. , 1970, Lancet.

[19]  D. Morton,et al.  Demonstration of antibodies against human malignant melanoma by immunofluorescence. , 1968, Surgery.

[20]  C. Southam.  Evidence for cancer-specific angigens in man. , 1967, Progress in experimental tumor research.

[21]  D. Dumonde.  Tissue-specific antigens. , 1966, Advances in immunology.

[22]  L. Hayflick.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.

[23]  B. Lytton,et al.  Antigenic Properties of Human Tumours: Delayed Cutaneous Hypersensitivity Reactions , 1964, British medical journal.

[24]  G. Klein,et al.  Demonstration of host resistance against isotransplantation of lymphomas induced by the Gross agent. , 1962, Cancer research.

[25]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[26]  T. Takaoka,et al.  The growth-promoting substances for Yoshida sarcoma cells in tissue culture. , 1959, The Japanese journal of experimental medicine.

[27]  E. Weiler.  A cellular change in hamster kidney cultures: Loss of tissue-specific antigens , 1959 .

[28]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[29]  E. J. Foley.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953, Cancer research.

[30]  L. Gross.  Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line , 1943 .